Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2019 Jun 18;139(25):e1046-e1081.
doi: 10.1161/CIR.0000000000000624. Epub 2018 Nov 10.

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Scott M Grundy  1 , Neil J Stone  1 , Alison L Bailey  1 , Craig Beam  1 , Kim K Birtcher  1 , Roger S Blumenthal  1 , Lynne T Braun  1 , Sarah de Ferranti  1 , Joseph Faiella-Tommasino  1 , Daniel E Forman  1 , Ronald Goldberg  1 , Paul A Heidenreich  1 , Mark A Hlatky  1 , Daniel W Jones  1 , Donald Lloyd-Jones  1 , Nuria Lopez-Pajares  1 , Chiadi E Ndumele  1 , Carl E Orringer  1 , Carmen A Peralta  1 , Joseph J Saseen  1 , Sidney C Smith Jr  1 , Laurence Sperling  1 , Salim S Virani  1 , Joseph Yeboah  1
Affiliations
Free article
Practice Guideline

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Scott M Grundy et al. Circulation. .
Free article

Erratum in

No abstract available

Keywords: AHA Scientific Statements; Guidelines; biomarkers, coronary artery calcium score; cardiovascular disease; cholesterol, LDL-cholesterol; diabetes mellitus; drug therapy; ezetimibe; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; pharmacological; primary prevention; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors; risk assessment; risk reduction discussion; risk treatment discussion, secondary prevention.

PubMed Disclaimer

Publication types

MeSH terms